• Gender equity progress: Biocon has achieved 50% female representation among its research staff on merit, although achieving gender parity on manufacturing shop floors remains challenging due to shift and security requirements.
• Female funding barriers: Women entrepreneurs continue to face credibility hurdles and capital-access constraints, largely driven by male-dominated venture capital teams and financial institutions.
• Regulatory and investment reforms: Accelerating domestic innovation requires urgent regulatory updates and a higher risk appetite from investors, who currently prioritize safe returns and dividends over scaling high-risk, disruptive ideas.
• Biology-driven AI innovation: Biological intelligence and DNA-based computing offer far greater energy and resource efficiency than conventional data centers, presenting major opportunities to disrupt traditional AI infrastructure.
• Biocon succession planning: Claire Mazumdar has been named as successor to lead Biocon and will initially join the board to spend several years learning the business and culture before taking over.